Literature DB >> 30600526

Intranasal sufentanil given in the emergency department triage zone for severe acute traumatic pain: a randomized double-blind controlled trial.

Fabien Lemoel1, Julie Contenti2,3, Charles Cibiera2, Jocelyn Rapp2, Céline Occelli2,3, Jacques Levraut2,3.   

Abstract

The goal of our study was to determine if an intranasal (IN) dose of sufentanil delivered in the ED triage zone would improve the management of severely painful patients. We performed a randomized, double blind and placebo-controlled trial on adult patients suffering from an acute severe pain (≥ 6/10) consecutive to an isolated limb injury. We compared 2 analgesic strategies: the usual pain treatment with IV-only multimodal analgesics (IVMA) including IV opioids if needed (control group) and another strategy (active group) based on a single dose of IN sufentanil (0.4 μg/kg) given at triage and followed by IV multimodal analgesia. Our primary outcome was the proportion of patients reaching pain-relief (≤ 3/10) 30 min after IN injection at triage. Secondary outcomes were rates of adverse events, frequency of clinical interventions required by these events, and satisfaction of patients. A total of 144 adult participants completed the study, 72 in each group. Compared with usual IV-only pain management, the analgesic strategy initiated in triage zone with a dose of IN sufentanil increased the proportion of patients reaching pain relief in 30 min: 72.2% versus 51.4%, in our trial (p = 0.01 and number needed to treat of 5). There was no serious adverse event (AE) in both groups. Patients who received IN sufentanil experienced more frequently minor opiate side effects. Proportion of respiratory AEs was higher in the active group (12.5% of bradypnea < 10 cycles per minute versus 1.4%) but these events were of mild severity, as only 2 participants (one in each group) received temporary low dose oxygen therapy, and none required naloxone. Lengths of stay in the ED were similar in both groups, as well as satisfaction of patients (above 9/10) and pain scores at discharge (< 2/10). We found that a single dose of IN sufentanil delivered in the ED triage zone significantly increases the proportion of severely painful patients reaching painrelief in 30 min, compared to usual analgesia with IV-only multimodal analgesia.

Entities:  

Keywords:  Acute severe pain; Emergency department; Intranasal; Limb injury; Non-invasive; Pain relief delay; Sufentanil; Time to analgesia; Triage nurse

Mesh:

Substances:

Year:  2019        PMID: 30600526     DOI: 10.1007/s11739-018-02014-y

Source DB:  PubMed          Journal:  Intern Emerg Med        ISSN: 1828-0447            Impact factor:   3.397


  4 in total

1.  Intranasal sufentanil given in the emergency department triage zone for severe acute traumatic pain-a randomized double-blind controlled trail: comment.

Authors:  Simon-Pierre Corcostegui; Damien Commeau; Julien Galant; Fabien Ramon; Cédric Boutillier du Retail
Journal:  Intern Emerg Med       Date:  2019-03-12       Impact factor: 3.397

2.  Intranasal sufentanil given in the emergency department triage zone for severe acute traumatic pain: a randomized double-blind controlled trail-reply.

Authors:  Fabien Lemoel; Jacques Levraut
Journal:  Intern Emerg Med       Date:  2019-04-17       Impact factor: 3.397

3.  Multimodal oral analgesia for non-severe trauma patients: evaluation of a triage-nurse directed protocol combining methoxyflurane, paracetamol and oxycodone.

Authors:  Damien Viglino; Nicolas Termoz Masson; Agnès Verdetti; Flore Champel; Cédric Falcon; Alexis Mouthon; Prudence Mabiala Makele; Roselyne Collomb Muret; Caroline Maindet Dominici; Maxime Maignan
Journal:  Intern Emerg Med       Date:  2019-07-09       Impact factor: 3.397

4.  Intranasal sufentanil versus intravenous morphine for acute severe trauma pain: A double-blind randomized non-inferiority study.

Authors:  Marc Blancher; Maxime Maignan; Cyrielle Clapé; Jean-Louis Quesada; Roselyne Collomb-Muret; François Albasini; François-Xavier Ageron; Stephanie Fey; Audrey Wuyts; Jean-Jacques Banihachemi; Barthelemy Bertrand; Audrey Lehmann; Claire Bollart; Guillaume Debaty; Raphaël Briot; Damien Viglino
Journal:  PLoS Med       Date:  2019-07-16       Impact factor: 11.069

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.